Re­searchers pan phar­ma DTC ad­ver­tis­ing for high spend­ing on low-val­ue drugs — JA­MA re­port

New re­search is look­ing to con­nect the dots be­tween di­rect-to-con­sumer (DTC) ad­ver­tis­ing and low­er clin­i­cal ben­e­fits or ther­a­peu­tic val­ue. A study pub­lished on Tues­day in JA­MA found that among the group of top-sell­ing drugs in 2020, brands that had a low­er added ben­e­fit spent more on DTC ad­ver­tis­ing.

The re­searchers from the Johns Hop­kins Bloomberg School of Pub­lic Health broke out 12 of the top spenders and ranked them by the high­est share of pro­mo­tion­al spend­ing that went to DTC ads. In­clud­ed in the group were Yer­voy (97.6% share on DTC), Ocre­vus (97.4%), Ibrance (95.8%) and Op­di­vo (92.2%).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.